Background-11␤-Hydroxysteroid dehydrogenase (11␤HSD) isozymes catalyze the interconversion of active and inactive glucocorticoids, allowing local regulation of corticosteroid receptor activation. Both are present in the vessel wall; here, using mice with selective inactivation of 11␤HSD isozymes, we test the hypothesis that 11␤HSDs influence vascular function. Methods and Results-Thoracic aortas were obtained from weight-matched male wild-type (MF1ϫ129 cross ϩ/ϩ ), 11␤HSD1 Ϫ/Ϫ , and 11␤HSD2 Ϫ/Ϫ mice. mRNA for both isozymes was detected in wild-type aortas by RT-PCR. 11␤HSD activity in aortic homogenates (48.81Ϯ4.65% conversion) was reduced in both 11␤HSD1 Ϫ/Ϫ (6.36Ϯ2.47% conversion; PϽ0.0002) and 11␤HSD2 Ϫ/Ϫ (24.71Ϯ3.69; Pϭ0.002) mice. Functional responses were unaffected in aortic rings isolated from 11␤HSD1 Ϫ/Ϫ mice. In contrast, aortas from 11␤HSD2 Ϫ/Ϫ mice demonstrated selectively enhanced constriction to norepinephrine (E max 4.28Ϯ0.56 versus 1.72Ϯ0.47 mN/mm; Pϭ0.004) attributable to impaired endothelium-derived nitric oxide activity. Relaxation responses to endothelium-dependent and -independent vasodilators were also impaired. To control for chronic renal mineralocorticoid excess, MF1 mice were treated with fludrocortisone (16 weeks) but did not reproduce the functional changes observed in 11␤HSD2 Ϫ/Ϫ mice. Conclusions-Although both 11␤HSD isozymes are present in the vascular wall, reactivation of glucocorticoids by 11␤HSD1 does not influence aortic function. Mice with 11␤HSD2 knockout, however, have endothelial dysfunction causing enhanced norepinephrine-mediated contraction. This appears to be independent of renal sodium retention and may contribute to hypertension in 11␤HSD2 deficiency. (Circulation. 2001;104:2832-2837.)
T he 11␤-hydroxysteroid dehydrogenase (11␤HSD) enzymes catalyze the interconversion of active and inactive glucocorticoids. Two isozymes have been identified: 11␤HSD2 1,2 is a dehydrogenase and converts cortisol (corticosterone in mice) into its inactive metabolite, cortisone (11-dehydrocorticosterone), whereas 11␤HSD1 3 is predominantly a reductase in vivo and regenerates cortisol from cortisone (corticosterone from 11-dehydrocorticosterone). 11␤HSD2 is expressed in the distal nephron, colon, and sweat glands, where it protects mineralocorticoid receptors from inappropriate activation by glucocorticoids (reviewed in Reference 4) . Deficiency or inhibition of 11␤HSD2 results in activation of renal mineralocorticoid receptors by glucocorticoids, producing the syndrome of "apparent mineralocorticoid excess," with its characteristic sodium retention, hypokalemia, and hypertension. 11␤HSD1 is expressed in many tissues in which mineralocorticoid receptors are not present, including liver and fat; its likely role is to reactivate glucocorticoids and thereby maintain activation of glucocorti-coid receptors at sites where they have most influence on metabolism. 4, 5 Both 11␤HSD1 and 11␤HSD2 are expressed in the vascular wall, although their exact localization remains unclear. 11␤HSD1 has been demonstrated in rat vascular smooth muscle, 6 and 11␤HSD2 has been detected in human vascular smooth muscle 7 and cultured rat endothelial cells. 8 Glucocorticoid and mineralocorticoid receptors are both expressed in blood vessels, and corticosteroids have diverse actions on vascular function. 9 The presence of 11␤HSDs suggests that they influence vascular function by regulating local concentrations of active glucocorticoids in the vascular wall. Inhibition of 11␤HSDs potentiates the effects of glucocorticoids in isolated vessels in vitro 10, 11 and in dermal and forearm circulation in vivo, 12, 13 but it is not clear which 11␤HSD isozyme is responsible for these effects. Isozyme-specific inhibitors of 11␤HSD are not available, and the nonselective inhibitor carbenoxolone damages endothelial cells in vitro. 14 We recently developed genetically manipulated mice deficient in either 11␤HSD1 5 or 11␤HSD2. 15 We have now used these to test the hypothesis that 11␤HSD isozymes influence vascular function in mice. We aimed to elucidate the respective importance of each isozyme, identify the pathways affected by glucocorticoid metabolism in the vessel wall, and assess the relevance of these changes in vascular function to hypertension.
Methods

Mice
11␤HSD-Knockout
Genetic inactivation of 11␤HSD1 5 and 11␤HSD2 15 isozymes was described previously. We investigated homozygous null (Ϫ/Ϫ) male mice from both transgenic groups and matched controls (first generation MF1ϫ129 cross). 11␤HSD1 Ϫ/Ϫ mice (nϭ10) were agematched (99Ϯ3 versus 100Ϯ2 days) and weight-matched (39Ϯ2 versus 37Ϯ1 g) with controls. 11␤HSD2 Ϫ/Ϫ mice (nϭ8) tended to be older (123Ϯ11 versus 98Ϯ4 days; Pϭ0.07) than weight-matched (37Ϯ2 versus 39Ϯ2 g) controls.
Chronic Mineralocorticoid Excess
Mineralocorticoid excess was produced in MF1 mice by subcutaneous implantation under halothane anesthesia of a pellet impregnated with fludrocortisone (50 mg as a 1:4 mixture of fludrocortisone acetate and Silastic elastomer (MDX4-4210; Dow Chemical Corp). 16 Six-week-old, male MF1 mice (Bicester, UK) were treated with a single fludrocortisone-impregnated (nϭ12) or elastomer-only (nϭ12) pellet for 102Ϯ8 days. Three fludrocortisone-treated mice were killed because of wound breakdown, and 1 control mouse was euthanized after injuring a forelimb.
Blood Pressure
Blood pressure in the knockout strains has been reported elsewhere. 5, 15 In mice treated with fludrocortisone or vehicle, systolic blood pressure was measured by tail-cuff plethysmography in conscious, restrained, warmed mice 17 from age 13 weeks (Ϸ30 g body weight).
Tissue Preparation
Mice were killed by cervical dislocation or decapitation, and organs were weighed. The entire thoracic aorta was removed into physiological saline solution (PSS) containing (mmol/L) NaCl 119, KCl 4.7, CaCl 2 2.5, MgSO 4 .7H 2 O 1.17, KH 2 PO 4 1.18, NaHCO 3 25, K 2 EDTA 0.026, and D-glucose 5.5). Two rings, 2 mm in length, were taken for immediate functional studies. Sections of tissues from knockout and control mice were frozen in dry ice and stored at Ϫ70°C for enzyme activity assays and reverse transcription-polymerase chain reaction (RT-PCR).
11␤HSD Activity
As previously described, 6, 18 aortas were homogenized in Krebs-Ringer buffer at pH 7.4, and protein was measured colorimetrically. In vitro, 11␤HSD1 is an NADP(H)-dependent 11␤-oxidoreductase, whereas 11␤HSD2 is exclusively an NAD-dependent 11␤dehydrogenase. Dehydrogenase activity was determined 6 
Detection of 11␤HSD mRNA
Total RNA was extracted from aorta, kidney, and liver from MF1 mice with TRIzol (Gibco) and quantified with UV spectroscopy. Total RNA (1 g) was reverse transcribed with oligo (dT) primers with a commercial kit (Promega). Ten to 100 ng reverse-transcribed RNA was primed with oligonucleotides specific for 11␤HSD 1 (5Ј-AAAGCTTG-TCACWGGGGCCAGCAAA-3Ј [where W indicates A or T] and 5Ј-AGGATCCARAGCA-AACTTGCTTGC-3Ј) and 11␤HSD 2 (5Ј-ACCCCTGCTTG-GCAGCCTACGGCA-3Ј and 5Ј-TCACATTAGT-CACTGCAGCTG TCTTGG-3Ј). RT-PCR was performed as described previously 19 with different annealing conditions for 11␤HSD1 (30 seconds at 56°C) and 11␤HSD2 (1 minute at 62°C). Aliquots of each RT-PCR reaction mixture (40 L aorta; 5 L kidney and liver) were electrophoresed on a 2% agarose gel that was stained with ethidium bromide and photographed under ultraviolet light.
Functional Investigations
Two rings from a test (transgenic or fludrocortisone-treated) animal and 2 from a control were analyzed in parallel. Each was suspended on 40-m wires in a myograph containing PSS at 37°C, perfused with 95% O 2 /5% CO 2 , for measurement of isometric force. The endothelium was removed from 1 ring from each mouse by rubbing the luminal surface, and the length of each ring was measured.
Normalization was achieved by stepwise incremental stretches of the vessel and application of the LaPlace relation (PϭT/r, where P is the transmural pressure, T is the wall tension, and r is the internal radius of the vessel) to determine the internal diameter under an effective intraluminal pressure of 13.3 kPa (l 100 ). Arteries were stretched to their optimum resting level (0.9 l 100 ). The arteries were contracted twice with NE-K (a mixture of 0.1 mol/L norepinephrine [NE] in KPSS [PSS containing 125 mmol/L K ϩ ]), once with NE alone, once with KPSS alone, and finally with NE-K. Cumulative concentration-response curves were obtained for 5-hydroxytryptamine (5-HT; 1 nmol/L to 30 mol/L), KCl (2.5 to 320 mmol/L), and NE (1 nmol/L to 3 mol/L). Vasodilator responses were obtained for acetylcholine (ACh; 1 nmol/L to 30 mol/L) and the nitric oxide (NO) donor 3Ј-morpholinosydnonimine (SIN-1; 1 nmol/L to 30 mol/L) in vessels precontracted with 0.3 mol/L 5-HT. The influence of the endothelium on adrenoceptor-mediated contraction made adrenoceptor agonists unsuitable for precontraction of these vessels. Preliminary investigations indicated that 5-HT was a suitable alternative.
In some vessels, concentration-response curves to NE were repeated after incubation (30 minutes) with the NO synthase (NOS) inhibitor N G -nitro-L-arginine (10 Ϫ4 mol/L).
Drugs
Fludrocortisone acetate was obtained from ICN Biomedicals Inc, SIN-1 from Alexis, [ 3 H]corticosterone from Amersham Life Sciences, high-performance liquid chromatography solvents from Rathburn Chemicals Ltd, and other chemicals from Sigma BDH.
Statistics
Results are meanϮSEM for n mice. Enzyme activities were compared by 1-way ANOVA. Contractions are expressed as force per unit length of vessel (mN/mm) and as percentage of the maximum response to KPSS (to control for vessel size). Relaxation is expressed as percentage of precontraction with 5-HT. Sensitivity to agonists is expressed as negative logarithm of the concentration necessary to produce 50% of maximum responses (pD 2 for constrictors; ϪlogIC 50 for dilators). Response curves for control and experimental tissues were compared by 2-way ANOVA with Tukey post hoc test. The effects of N G -nitro-L-arginine were analyzed by Student's paired t tests.
Results
Detection of mRNA for 11␤HSD Isozymes in Normal Mouse Aorta
RT-PCR amplification products of 450 and 144 bp for 11␤HSD1 and 11␤HSD2, respectively, were detected in aortas (Figure 1a ). 11␤HSD2 mRNA was also detected in kidney, but not liver, whereas 11␤HSD1 mRNA was identified in both tissues.
11␤HSD-Knockout
As described previously, 15 11␤HSD2 Ϫ/Ϫ mice had enlarged kidneys (1.08Ϯ0.05% body weight) compared with controls (0.82Ϯ0.05% body weight; Pϭ0.002).
Enzyme Activity
NAD-dependent and NADP-dependent enzyme activities were similar in aortas from wild-type mice (nϭ12). Enzyme activities were reduced, but not abolished, in 11␤HSD1 Ϫ/Ϫ mice ( Figure  1b, PϽ0.001; nϭ10 ). Activities were also lowered in mice lacking 11␤HSD2 (nϭ6), but to a much lower degree ( Figure  1b) , with the reduction in NAD-dependent activity achieving only borderline significance (Pϭ0.055).
Vascular Function in 11␤HSD1
؊/؊ Mice NE-mediated contraction was similar in intact aortic rings from 11␤HSD1 Ϫ/Ϫ and wild-type mice (Figure 2a ). Both removal of the endothelium (Figure 2a ) and inhibition of NOS (not shown) increased the amplitude of this response equally in both groups. NOS inhibition had no effect on denuded arteries (not shown). Contractile responses to 5-HT and KCl (Table 1) and dilator responses to ACh and SIN-1 ( Table 2) were also similar in aortas from 11␤HSD1 Ϫ/Ϫ and wild-type mice.
Vascular Function in 11␤HSD2 ؊/؊ Mice
In contrast, in intact aortas from 11␤HSD2 Ϫ/Ϫ mice, NEmediated contraction was substantially greater than in wild- type controls and was unaffected by removal of the endothelium (Figure 2b) . Thus, responses to NE in intact and denuded aortas from 11␤HSD2 Ϫ/Ϫ mice were similar to those of denuded vessels from wild-type mice. Aortas from 11␤HSD2 Ϫ/Ϫ mice also showed enhanced contractile sensitivity to KCl (Table 1) , but this was much less substantial than the difference in NE responsiveness and was not endothelium-dependent. Contraction to 5-HT was not different in 11␤HSD2 Ϫ/Ϫ and wild-type mice ( Table 1) . Inhibition of NOS enhanced the response to NE in intact (but not denuded) aortas from wild-type (1.47Ϯ0.36 versus 3.54Ϯ0.46 mN/mm; PϽ0.001; nϭ12) but not 11␤HSD2 Ϫ/Ϫ (4.25Ϯ0.73 versus 4.94Ϯ0.73 mN/mm; Pϭ0.29; nϭ5) mice. Responses to ACh were impaired in aortas from 11␤HSD2 Ϫ/Ϫ mice (Figure 3a ). Responses to SIN-1 were potentiated by removal of the endothelium but were impaired in aortas from 11␤HSD2 Ϫ/Ϫ mice whether or not the endothelium was present (Figure 3b ).
TABLE 1. Maximum Contraction (E max ) and Sensitivity (pD 2 ) to NE, 5-HT and KCl in Aortas From 11␤HSD ؊/؊ Mice and Controls (؉/؉)
Chronic Exogenous Mineralocorticoid Excess
Implantation of fludrocortisone pellets temporarily interrupted weight gain (for Ϸ7 days). Fludrocortisone increased heart weight (0.63Ϯ0.02% body weight versus 0.50Ϯ0.03% body weight; Pϭ0.006) and kidney weight (0.91Ϯ0.07% body weight versus 0.77ϩ0.02% body weight; Pϭ0.04) but had no effect on liver, adrenal, and thymus weights. A trend toward higher systolic blood pressure induced by fludrocortisone was not significant (123Ϯ7 mm Hg [nϭ8] versus 116Ϯ5 mm Hg [nϭ9]; Pϭ0.38).
Vascular Function
NE-mediated contraction was not significantly different in aortas from mice receiving fludrocortisone or vehicle (Figure 4) , although there was a trend for a small increase in responsiveness to NE with fludrocortisone in intact vessels. Contractile responses to 5-HT and KCl and dilator responses to ACh and SIN-1 were unaffected by fludrocortisone (Table 3) .
Discussion
This investigation, using unique 11␤HSD Ϫ/Ϫ mice, clarifies a number of contentious issues concerning the role of 11␤HSD enzymes in vascular tissue. We conclude that both isozymes are present in the mouse aorta. Furthermore, 11␤HSD2, rather than 11␤HSD1, influences vascular tone in mice. Thus, inhibition of 11␤HSD2 is likely to account for previously observed effects of nonselective 11␤HSD inhibitors on vas-cular function in vitro 10, 11, 20 and in vivo. 12, 13, 21 11␤HSD2 appears to mediate its effect on vascular function directly in the vessel wall, rather than indirectly through its actions in the kidney, because vascular changes in 11␤HSD2 deficiency were not reproduced by chronic renal mineralocorticoid excess induced by fludrocortisone administration. Finally, the altered vascular function associated with 11␤HSD2 deficiency is consistent with impaired inactivation of glucocorticoids in endothelial cells, resulting in inhibition of NO generation and thus enhanced contractility to NE.
Enzyme activities and RT-PCR show both 11␤HSD isozymes in mouse aorta. Their cofactor specificity is not as clear-cut as in rat, 18 and similar activities were observed with NAD and NADP. 11␤HSD1 has been detected in several Results are meanϮSEM for aortas from (n) mice.
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blood vessels, 6 but data for 11␤HSD2 are inconsistent. 7 11␤HSD1 Ϫ/Ϫ mice have negligible 11␤HSD activity at sites at which only the type 1 isozyme is expressed (eg, liver) but normal 11␤HSD2 activity (eg, in kidney). 5 Therefore, the residual activity in aortas from these mice indicates the presence of 11␤HSD2. Moreover, this is not "compensatory" for knockout of 11␤HSD1, because mRNA for both isozymes was detected in wild-type aorta. The residual activity in 11␤HSD1 Ϫ/Ϫ aortas and the modest effect of 11␤HSD2knockout on activity are consistent with mouse 11␤HSD2 expression being restricted to endothelial cells, 8 whereas 11␤HSD1 is expressed in vascular smooth muscle cells. 6 The small contribution to total activity made by 11␤HSD2 could thus reflect the relative sparsity of endothelial cells. Potent inactivation of glucocorticoids may occur, however, within the endothelium. Before the cloning of 11␤HSD2 1,2 and recognition of 11␤HSD1 as a predominant reductase in other cells, 4 the ability of 11␤HSD inhibitors to potentiate the effects of glucocorticoids on vascular function 10 -13 was attributed to inhibition of 11␤HSD1 dehydrogenase activity. Recent data also suggest that inhibition of dehydrogenase activity (by either isozyme) is functionally important. 20, 21 In vivo dehydrogenase activity of vascular 11␤HSD1 has not been excluded by the present investigation, but the marked contrast between the effects of knockout of the 2 isozymes suggests that 11␤HSD2 provides the major vascular dehydrogenase activity, loss of which results in increased intracellular glucocorticoid levels and impaired action of the endothelium-derived NO system. The role, if any, of 11␤HSD1 in the vessel wall remains obscure.
11␤HSD2 also has important effects elsewhere. Loss of renal 11␤HSD2 results in activation of mineralocorticoid receptors by glucocorticoids. 15 Previous investigations, however, suggest that this is unlikely to account for the changes in vascular function. In hypertensive models, increased contractile responses occur with most agonists and are not endothelium-dependent. Moreover, induction of renal mineralocorticoid excess with deoxycorticosterone acetate and salt in rats resulted in enhanced endothelial NO generation, 22, 23 rather than impaired NO activity. Finally, 11␤HSD inhibitors affect vascular function in isolated vessels 10, 11 as well as in vivo. 12, 13 Possible indirect effects of renal 11␤HSD2 inhibition were addressed by chronic fludrocortisone administration to MF1 mice. This reproduced the cardiac and renal hypertrophy detected in 11␤HSD2 Ϫ/Ϫ animals, but not the abnormalities of vascular function. Blood pressure in fludrocortisone-treated mice was not as high as in 11␤HSD2 Ϫ/Ϫ mice; this is not surprising, because induction of mineralocorticoid hypertension in rodents usually requires salt loading and/or partial nephrectomy. It is possible, however, that either the vascular dysfunction is indirectly mediated in 11␤HSD2 Ϫ/Ϫ mice by more severe hypertension or vascular dysfunction in the 11␤HSD2 Ϫ/Ϫ mice explains their more severe hypertension. The difference between 11␤HSD2 Ϫ/Ϫ and fludrocortisone-treated mice also suggests that vascular dysfunction in 11␤HSD2 Ϫ/Ϫ mice is not mediated by vascular mineralocorticoid receptors and is most likely to be mediated by the glucocorticoid receptor. 
